Web Results

Cipher Pharmaceuticals

www.cipherpharma.com/

Cipher Pharmaceuticals is a growing specialty company with a focus on dermatology. Our goal is to develop and acquire best-in-class skin care solutions.

Cipher Pharmaceuticals acquires INNOCUTIS Holdings ... - Onxeo

www.onxeo.com/site/wp-content/uploads/2015/04/150413EN_Sitavig.pdf

Apr 13, 2015 ... oncology drugs, today announced Cipher Pharmaceuticals' (NASDAQ: CPHR) acquisition of INNOCUTIS. Holdings LLC, the licensee of ...

innocutis | CrunchBase

www.crunchbase.com/organization/innocutis

Innocutis is a pharmaceutical and medical device company developing therapeutic ... Founded: 2005; Aliases: Innocutis Holdings, LLC; Contact: 843- 965-8333 ...

Charles F. Jenkins | LinkedIn

www.linkedin.com/in/charles-f-jenkins-b1043732

Cipher Pharmaceuticals Inc. Previous. Innocutis Holdings, LLC,; Innocutis Medical, LLC,; Medicis. Education. University of South Carolina-Columbia. Websites.

DailyMed - UMECTA PD UREA- urea emulsion

dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ce953fdf-a73a-4f7e-8946-959346990626

More Info For This Drug. View Label Archives; RxNorm; Get Label RSS Feed. NDC Code(s): 68712-017-01, 68712-017-02; Packager: Innocutis Holdings LLC.

Cipher Pharma maps out its path to success - The Globe and Mail

www.theglobeandmail.com/globe-investor/investment-ideas/cipher-pharma-maps-out-its-path-to-success/article24053442/

Apr 21, 2015 ... ... company Innocutis Holdings LLC for $45.5-million (U.S.) in cash, its ... Innocutis gives Cipher critical infrastructure to sell its products in the ...

DailyMed - UMECTA UREA- urea film

dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd7b3fe5-8ba6-4808-8ead-1b20a87a2ed2

NDC Code(s): 68712-010-01, 68712-010-03, 68712-010-04; Packager: Innocutis Holdings LLC. Category: HUMAN PRESCRIPTION DRUG LABEL; DEA ...

DailyMed - UMECTA MOUSSE UREA - urea foam aerosol, foam

dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=53f903a2-2b5c-4584-8e91-2c9f41b883ea

NDC Code(s): 68712-020-01; Packager: Innocutis Holdings LLC. Category: HUMAN PRESCRIPTION DRUG LABEL; DEA Schedule: None; Marketing Status:  ...

GLYCOBIOSCIENCES, INC. v. INNOCUTIS HOLDINGS, LLC et al

search.rpxcorp.com/lit/dcdce-157041-glycobiosciences-v-innocutis-holdings

GLYCOBIOSCIENCES, INC. v. INNOCUTIS HOLDINGS, LLC et al. 1:12-cv- 01901; Filed: 11/25/2012; Case Updated Daily; Latest Docket Entry: 08/17/2016 ...

BioAlliance Pharma: Sitavig® Licensing Strategy | Business Wire

www.businesswire.com/news/home/20140318006415/en/BioAlliance-Pharma-Sitavig®-Licensing-Strategy

Mar 19, 2014 ... Execution of licensing agreement with Innocutis for North America ... with Innocutis Holding LLC to commercialize Sitavig® in North America.

More Info

Cipher Pharmaceuticals announces U.S. commercial entry through ...

www.prnewswire.com

Apr 13, 2015 ... ... that it has acquired INNOCUTIS Holdings LLC ("INNOCUTIS"), a privately held specialty dermatology company, for US$45.5 million in cash.

Innocutis Holdings LLC - Company Profile - BioCentury

www.biocentury.com

Apr 2, 2012 ... Innocutis' detailed financings; Comprehensive pipeline breakdown, including molecular targets & partnerships. 17 years of in-depth BioPharma ...

Innocutis Holdings LLC Licenses Sitavig from BioAlliance Pharma

sitavig.com

Mar 19, 2014 ... Innocutis Holdings LLC is pleased to announce the licensing of Sitavig® ( ACYCLOVIR) 50mg Buccal Tablets, from BioAlliance Pharma for ...